AOA Dx was selected for MassChallenge’s 2022 US Early-Stage Cohort

AOA Dx is excited to share that the company has been selected to participate in the MassChallenge 2022 accelerator program, joining more than 200 startups. AOA Dx was one of over 1,000 other startup applications for this year’s program.

“My team and I are so proud to be accepted to MassChallenge’s 2022 US Early-Stage Cohort. This has been one of our goals since we started the company and feel honored to be among such an inspiring group of entrepreneurs. We look forward to the continued growth and knowledge we will gain from this experience.” – said Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx.

By participating in this accelerator, AOA Dx will receive unrivaled access to a global network of partners, experts, and mentors; residency options; market access opportunities; and more to bolster our efforts to impact women’s health.

As part of the program, AOA Dx aims to strengthen its development program and growth strategy, as well as prepare for the next round of financing.

About MassChallenge

MassChallenge is the global network for innovators. Headquartered in the United States with eight locations worldwide, it is the non-profit’s mission to help bold entrepreneurs disrupt the status quo and create sustainable change. Since launching in 2009, MassChallenge has run programs in 18 countries, supported more than 3,000 startups from around the world, and awarded over $17M in equity-free cash and prizes. Learn more about MassChallenge at

About AOA Dx Inc.

AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at

Corporate Communications